What is Tapering Off GLP-1s?

Most people using Ozempic, Wegovy, or Mounjaro spend months focused on losing weight. Far fewer think about how they will transition off the medication when the time comes, having reached their target weight. Yet all of the data suggests that this is where the real challenges begin. As the drug leaves your system, your appetite will start to return, and old habits re-emerge. The question shifts from how well the medication works to what happens without it. And the questions around “What is tapering and is it right for me?” start to take hold.

Tapering off GLP-1 medication is often suggested as a way to make that transition phase feel more manageable. But what does tapering actually mean, and does it make a meaningful difference?

What is The Difference Between Microdosing and Tapering?

Before we go further, it helps to be precise about what the two terms, tapering and microdosing, mean and confirm that, contrary to general belief, they are distinctly different approaches, each tailored to the unique needs of the individual.

• Tapering refers to gradually reducing the dose over time with the intention of stopping completely. It is a transition process, designed to move from full treatment to no medication while allowing appetite and eating patterns to adjust more gradually.
• Microdosing, by contrast, usually involves continuing on a lower dose for a longer, sometimes indefinite period. Rather than working towards stopping, it is often used as a way to maintain some level of appetite control or to delay coming off the medication entirely.

Think of it This Way

Tapering is like walking slowly out of the deep end of a pool until you reach dry land. Microdosing is like staying in the shallow end, never fully out of the water but not submerged either. The key difference is the end goal. Tapering is a pathway towards stopping. Microdosing is often a way of extending the use of the medication at a reduced level.

Both approaches can make the transition feel less abrupt. However, neither replaces the need to address what happens when the medication is no longer doing the work. Long-term weight stability still depends on how you respond to returning appetite, structure your environment and manage habits once the support of the medication is reduced or removed.

What Does Tapering Off GLP-1 Medication Mean?

Tapering simply means gradually reducing the dose of the medication over a few months rather than stopping it suddenly. Many users who adopt this approach also start to reduce the frequency of the injections. Some stretch the period from seven days, initially to ten, then slowly increase the period, lowering their dependence on the GLP-1 medication.

The idea is to give your body and appetite time to adjust. Rather than going from full appetite suppression to none at all, tapering creates a more gradual shift. For many people, this can feel less abrupt and easier to manage in the short term.

The tapering approach essentially reverses the standard treatment protocol for GLP‑1s, which typically involves gradually increasing the dose over time. Instead, the process is flipped: for Wegovy, for example, doses may be reduced in stages from 2.4 mg to 1.7 mg, then to 1.0 mg. Similarly, with Mounjaro, the dose might be stepped down from 7.5 mg to 5 mg, then to 2.5 mg as part of a gradual exit strategy.

There is some evidence that patients following this approach find the transition less troublesome when ceasing the medication.

Is Tapering Necessary?

In most cases, tapering is not medically required, as it is for certain other medications. However, that doesn’t mean it has no value.

Many people find tapering helpful because it provides a transition period. It allows time to notice changes in hunger, eating patterns and decision-making. It also creates space to begin putting new routines in place before the medication is fully removed. The key point is this: tapering can support the process, but it does not replace the need for a clear plan.

What Happens if You Stop GLP-1 Medication Suddenly?

When GLP-1 medication is stopped, several changes occur: appetite returns, food becomes more noticeable again, the volume of the ‘food noise’ starts to increase and the sense of control that felt easy during treatment can start to slip away. Without preparation, people often drift back into previous habits. This is not a lack of willpower; it’s a predictable response to the removal of a powerful appetite-regulating tool.

Does Tapering Prevent Weight Regain?

Tapering may make the transition off the medication feel smoother, but on its own, it doesn’t prevent weight regain and it doesn’t address what replaces it. Weight maintenance after GLP-1 medication depends far more on behaviour than dosage. How you respond to returning appetite, how you structure your environment and how you manage triggers will ultimately determine whether the weight stays off. And unfortunately, this is where most people feel unprepared, because this part of the process is rarely explained in detail.

Why The GLP-1 Legacy Was Written

A new book, The GLP-1 Legacy, was written to address the void that exists around the often non-existent aftercare required to help users transition off GLP-1s, whilst not regaining the lost weight. It draws on over 15,000 hours of behavioural work with clients, combined with real experiences from GLP-1 users, to explain what happens after the injections stop and how to respond to it. It covers managing returning appetite, handling triggers, rebuilding structure and creating a realistic plan for long-term weight stability. The book includes an introduction by Professor Jane Ogden, health psychologist at the University of Surrey.

The GLP-1 Legacy book includes a complete section on both tapering and microdosing. It introduces research data on both approaches and provides in-depth guidelines to users on how to implement the different approaches safely.

If you’re not sure whether getting your hands on a copy of the book is the right move, then why not visit the book’s page on Amazon and read the many global reviews from both GLP-1 users and clinicians? That will give you a clear sense of how it’s being used in practice and the difference it’s making for people around the world who are navigating life after the medication.

Any decision to taper or adjust your GLP-1 medication should be made in consultation with your prescribing clinician. This information is intended to support understanding, not replace personalised medical advice.

FAQs

Martin and Marion’s groundbreaking work has been featured in prominent newspapers such as The Daily Mail, The Times, The Telegraph, and The Express. Leading magazines like Vogue, Marie Claire, Good Housekeeping, and Reader’s Digest have also recognised their contributions. The Shirrans and several of their clients have also made television appearances on both sides of the Atlantic.

Over a thousand individuals, including medical professionals, celebrities, and the general public, have travelled from around the world to experience their weight-loss treatment. Some sought to enhance their appearance, while others prioritised their health, successfully reversing medical conditions like insulin resistance, diabetes, high blood pressure, and fatty liver disease.

Martin and Marion Shirran

Marion Shirran, as a director of Oxford Therapeutics Limited, is proud to be a registered Stakeholder in NICE – the National Institute for Health and Care Excellence. Additionally, she is involved in the government’s All-Party Parliamentary Group on Obesity.

They were awarded the ‘Most Innovative Obesity Psychological Therapy Service’ in the UK Mental Health Awards 2022. They are also co-authors of two bestselling books on the topic of non-surgical weight loss, published by Hay House.

---